Compare WLFC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | PCRX |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 1996 | 2011 |
| Metric | WLFC | PCRX |
|---|---|---|
| Price | $178.51 | $20.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.33 |
| AVG Volume (30 Days) | 61.3K | ★ 1.0M |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | 0.47 |
| Revenue | $674,381,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $16.17 | $6.21 |
| Revenue Next Year | $1.26 | $8.26 |
| P/E Ratio | ★ $10.91 | $42.12 |
| Revenue Growth | ★ 29.58 | 3.14 |
| 52 Week Low | $114.01 | $18.80 |
| 52 Week High | $211.00 | $27.64 |
| Indicator | WLFC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 37.80 |
| Support Level | $181.41 | $18.80 |
| Resistance Level | $189.45 | $21.12 |
| Average True Range (ATR) | 7.41 | 1.23 |
| MACD | 0.72 | -0.20 |
| Stochastic Oscillator | 71.75 | 21.91 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.